linjc16/ctgov huggingface dataset:
The Treatment of Bronchopulmonary Dysplasia by Intratracheal Instillation of Mesenchymal Stem Cells

Study Overview
=================
Brief Summary
-----------------
To study the effect and saftey of intratracheal instillation of mesenchymal stem cells for treatment BPD

Detailed Description
-----------------
This is a Phase 1 clinical trial that constitues two points cohorts with 100 participants per cohort who will receive instillation dose of mesenchymal stem cells-25 million cells/kg,with ventilation after 14 days.And the placebol will be 0.9% sodium choride. The investigator will proceed the groups during the same period. Deographic Data and Baseline charateristics of the studied groups were collected: Gestational age (weeks) Birth weight (g) gender Cesarean section delivery Antenatal steroids Prolonged rupture of membrane Multiple pregnancies APGAR score at 5 minutes mesenchymal stem cels dose is 25 million cells/kg Assessment the incidence of BPD after instillation of Mesenchymal stem cells the adverse after instillation of Mesenchymal stem cells

Official Title
-----------------
The Treatment of Bronchopulmonary Dysplasia by Intratracheal Instillation of Mesenchymal Stem Cells

Conditions
-----------------
Safety Issues, Effect of Drugs

Intervention / Treatment
-----------------
* Other: mesenchymal stem cells therapy
* Drug: 0.9% sodium chloride


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: twenty-eight weeks to thirty-seven weeks prematures who need ventilaton for 14 days after birth, and the oxygen concentration is more than 30% Exclusion Criteria: Preterm infants with major congenital malformations, chromosomal anomalies, inborn errors of metabolism and clinical or laboratory evidence of a congenital infection

Ages Eligible for Study
-----------------
Minimum Age: 28 Weeks
Maximum Age: 37 Weeks

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Placebo<br>0.9% sodium chloride intratracheal instillate on 14 days after birth | Drug: 0.9% sodium chloride<br>* 0.9% sodium chloride in control group<br>|
| Experimental: mesenchymal stem cells<br>mesenchymal stem cells intratracheal instillate on 14 days after birth ,dose is 25 million cells/kg | Other: mesenchymal stem cells therapy<br>* mesenchymal stem cells treatement of BPD for safety and effect evaluation0.9% sodium chloride incontrol group<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of patients with BPD after instillation mesenchymal stem cells | incidence of BPD | up to 28 days after birth | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
mesenchymal stem cells, safety, effect, BPD
Two Cases of Pulmonary Cysticercosis Manifesting as Pleural Effusion: Case Report and Literature Review

Study Overview
=================
Brief Summary
-----------------
Isolation lung cysticercosis reports are rare in literature. Most lung lesions were characterized by nodules. The investigators access one case which was characterized with pulmonary cavity and pleural effusion by Gupta N, et al in 2015 from PUBMED and Medline. But pleural effusion and exudative lesions is reported for the first time.

Detailed Description
-----------------
Cysticercosis is an important public health problem in developing countries. The major involvement sites are the central nervous system and the eyes，although striated muscles and subcutaneous tissues are frequently involved in the disseminated form of disease. Pulmonary involvement in cysticercosis is very rare and ill-defined nodular shadows distributed throughout the lung is the usual radiological presentation. Only one case of cysticercosis presenting as lung cavity with pleural effusion has been reported so far in literature. The investigators describe two cases in which pleural effusion due to cysticercosis were detected on X and CT.

Official Title
-----------------
Two Cases of Pulmonary Cysticercosis Manifesting as Pleural Effusion: Case Report and Literature Review

Conditions
-----------------
Cysticercosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of Pulmonary Cysticercosis。 With pleural effusion Exclusion Criteria: 1.No cysticercosis was found by biopsy or antibody test

Ages Eligible for Study
-----------------
Minimum Age: 45 Years
Maximum Age: 67 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Amount of pleural effusion | cm | 9 months | 
| Rate of Eosinophil ratio | Percentage（%） | 9 months | 
| Changes of lesions under chest radiography or CT | no change, change, complete absorption | 9 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cysticercosis, pleural effusion, pulmonary
Fingolimod Real World Experience: the French Grand-Est Cohort

Study Overview
=================
Brief Summary
-----------------
Objectives: This study describes efficacy and safety of Fingolimod in patients treated for at least 6 months in the east of France from January 2011 to December 2014. Background: The Grand-Est is a geographical region in France with a high prevalence of multiple sclerosis (more than 10000 patients registered in the European Database for Multiple Sclerosis (EDMUS) database). In this region and since January 2011, more than 1014 patients have been treated for at least 6 months with Fingolimod, the first oral therapy for patient with very active relapsing-remitting MS. Methods: Features of patients followed up in the Grand-Est region and treated with fingolimod in the 6 university hospitals, general hospitals and private neurologists were reviewed in a retrospective study after identification of the clinical files reported in the EDMUS database.

Official Title
-----------------
Fingolimod Real World Experience: the French Grand-Est Cohort

Conditions
-----------------
Multiple Sclerosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with MS treated with Gilenya because of the disease Exclusion Criteria: contraindications of Gilenya treatment or receiving Gilenya after the 31st of March 2014

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the course of the disease by magnetic resonance imaging (MRI) |  | assessed between January 2012 and September 2014, up to a total of 32 months |
Chemical Ice Packs for Cooling Hyperthermic Patients

Study Overview
=================
Brief Summary
-----------------
A common tool to cool people in the pre-hospital setting is the chemical ice pack. These are used by athletic trainers, EMS personnel, ER staff, and people in the prehosoital setting. The ability of these to cool a person has never been quantified, the efficiency and extent of cooling, as well as location of placement of ice packs is purely anecdotal. The purpose of this study is to determine whether strategically placed chemical ice packs will provide benefit to individuals subjected to heat stress.

Official Title
-----------------
Randomized Controlled Trial Assessing Effectiveness of Chemical Cold Packs Used on Various Skin Surfaces for Cooling Hyperthermic Patients

Conditions
-----------------
Heat Stroke, Heat Exhaustion

Intervention / Treatment
-----------------
* Other: Chemical Cold Pack


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: young healthy males > 18 years old with no active medical problems and able to run 10 km. Exclusion Criteria: Active medical problems or inability to exercise for 45 minutes in a heated room.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Chemical Ice packs to neck, groin, axillae<br>Chemical ice packs will be changed out every 9 minutes | Other: Chemical Cold Pack<br> <br> |
| Experimental: Chemical Ice Packs to cheeks, palms, soles<br>Chemical Ice packs will be changed out every 9 minutes | Other: Chemical Cold Pack<br> <br> |
| No Intervention: no chemical ice packs<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Core body temperature cooling |  | 35 minutes |
Arsha Vidya Program for Preventing Drug Abuse Among Disadvantaged Children in Urban Slums

Study Overview
=================
Brief Summary
-----------------
Substance abuse remain critical problems in both developed and developing countries. Under privileged communities where health and economic system is weakest, use of drugs and illicit substances starts during adolescence and young adulthood. This not just affect physical development, mental health and social integration, but also family formation and stability, deviant behaviour, sexual behaviour and involvement, educational pursuits, livelihood pursuits. Therefore, emphasises the need for preventive education at this impressionable age.

Official Title
-----------------
Arsha Vidya Program for Preventing Drug Abuse Among Disadvantaged Children in Urban Slums

Conditions
-----------------
Drug Abuse

Intervention / Treatment
-----------------
* Behavioral: Arsha Vidya program


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Parental consent to participate Exclusion Criteria: Family not involved in de-addiction program Planning to move the area Mental incapacity to consent or participate

Ages Eligible for Study
-----------------
Minimum Age: 7 Years
Maximum Age: 13 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Intervention Model: Single Group Assignment
Interventional Model Description: Quasi experimental design
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Arsha Vidya Program<br>Arsha Vidya outreach community program was conducted with children. An unique well-planned teaching program developed to educate Indian cultural values & heritage to young children and adults with yoga, chants, religious and spiritual practices through stories, group activities and plays. | Behavioral: Arsha Vidya program<br>* Integrated intervention program includes counselling and supportive care with the support of Arsha Vidya program<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percent days abstinent of tobacco, alcohol and drugs | Daily Dairy was given to assess days abstinent of tobacco, alcohol and drugs | change from baseline to 12-weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Well being | The Well-Being Index (WBI), 5-item scale used to assess changes in general well-being. | change from baseline to 12-weeks |
Metabolic and Infectious Diseases in La Réunion (the REUNION Population-based Study)

Study Overview
=================
Brief Summary
-----------------
The aim of the present study is to determine the prevalence of cardiometabolic and infectious disease in La Reunion (french oversea department and region of France). Known or suspected risk factor for these diseases will also be assessed, such as microbiota, cognitive impairement, social inequalities, and genetics.

Detailed Description
-----------------
Overall, 2000 men and women will be recruited during two years for an extensive clinical examination including a microbiota, blood, hair and DNA collection, cognitive tests, autonomous nervous system assessment, spirometry, pulse wave velocity measurement, a carotid doppler echo tracking.

Official Title
-----------------
Pathologies métaboliques et Infectieuses en Population générale à La Réunion : étude REUNION

Conditions
-----------------
Infectious Disease, Cardiovascular Diseases, General Population, Metabolic Disease

Intervention / Treatment
-----------------
* Diagnostic Test: Blood, DNA, feces, urine, hair and skin microbiota collection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18-67 years given consent for genetic analysis, written consent for participating in the study Exclusion Criteria: judicial protection or guardianship

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 67 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| general population<br>Observational study of 2000 adult men and women from the general population who will benefit from a free extensive health check up in La Reunion | Diagnostic Test: Blood, DNA, feces, urine, hair and skin microbiota collection<br>* See above<br>* Other names: ankle brachial index measurement;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of cardiometabolic diseases | Prevalence rates for diabetes, hypertension, obesity, dyslipidemia, smoking and subclinical atherosclerosis markers | cross sectional (at inclusion) | 
| Prevalence of infectious diseases | Seroprevalence rates for chikungunya, dengue, zika, covid19 | cross sectional (at inclusion) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
epidemiology, risk factors, prevalence, cognitive impairment, dengue, hypertension, dyslipidemia, social inequalities, autonomous nervous system
Pregnancy, Nitrate, Endothelial Function and Tissue Oxygen Saturation

Study Overview
=================
Brief Summary
-----------------
Adequate macro and microvascular endothelial function during pregnancy is essential for the normal placental development and growing fetus. Beetroot juice (BJ) promotes improvement ins this parameters in no-pregnant individuals, however the beneficial effect did not avaliated in pregnant. The present study evaluated effects of BJ on macro and microvascular endothelial function in pregnant. Twelve pregnant were submitted to BJ and nitrate-depleted juice (PLA) interventions. Brachial flow-mediated dilation (FMD) and muscle oxygenation were measured 120 min after interventions. Urinary nitrate, nitrite were measured at baseline and 120 min after interventions.

Official Title
-----------------
Effect of Beetroot Juice Consumption on Endothelial Function and Tissue Oxygen Saturation in Pregnant

Conditions
-----------------
Pregnancy

Intervention / Treatment
-----------------
* Other: Beetroot juice
* Other: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: gestation between 20 and 35 weeks; over 18 years Exclusion Criteria: diabetes mellitus and gestational diabetes; hypertensive syndromes; HIV positive; liver or kidney disease; beetroot allergy; use of antioxidants and medicament that alter endothelial function; use of antibiotics up to 2 weeks before the visits and using.
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Beetroot Juice<br>Beetroot juice containing 9 mmol of nitrate per dose | Other: Beetroot juice<br>* 140 mL of beetroot juice cointaning approximately 9 mmol of nitrate<br>|
| Placebo Comparator: Placebo juice (nitrate depleted)<br>Beetroot juice nitrate-depleted | Other: Placebo<br>* 140 mL of beetroot juice isent of nitrate<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Macro endothelial function | Flow-mediated dilation (FMD) | Evaluated 120 minutes after the nutritional intervention | 
| Micro endothelial function | Tissue oxygen saturation parameters | Evaluated 140 minutes after the nutritional intervention | 
| Nitrate urinary |  | Evaluated 150 minutes after the nutritional intervention | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Dietary nitrate, Nitrate, Flow-mediated dilation, Tissue oxygen saturation
Acute Kidney Injury Following Cardiac Surgery

Study Overview
=================
Brief Summary
-----------------
Acute kidney injury (AKI) occurs in approximately one-third of patients undergoing cardiac surgery (CS), and represents one of the most significant negative predictors of patient outcome in this population. The investigators sought to examine the risk factors associated with the development of AKI and renal recovery in patients undergoing cardiac surgery at San Bortolo Hospital, Italy 2014-2015.

Detailed Description
-----------------
Acute kidney injury (AKI) occurs in approximately one-third of patients undergoing cardiac surgery (CS), and represents one of the most significant negative predictors of patient outcome in this population. The investigators sought to examine the risk factors associated with the development of AKI and renal recoveryin patients undergoing cardiac surgery at San Bortolo Hospital, Italy during November 2014 - October 2015.

Official Title
-----------------
Acute Kidney Injury After Cardiac Surgery - A Retrospective Single-center Study

Conditions
-----------------
Acute Kidney Injury

Intervention / Treatment
-----------------
* Other: No intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Adult cardiac surgery Exclusion Criteria: Missing baseline serum creatinine (defined as a serum creatinine value within 90 prior to surgery) or missing serum creatinine within 3 days before hospital discharge Stage 5 chronic kidney disease (estimated glomerular filtration rate <15 ml/min/1.73 m2 or receipt of chronic dialysis) Solid organ transplant recipients
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cardiac Surgery Patients<br>All adult patients undergoing cardiac surgery (elective/emergent) at San Bortolo Hospital, Vicenza, Italy during November 2014 - October 2015 | Other: No intervention<br>* No intervention<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of acute kidney injury using full Kidney Disease Improving Global Outcomes criteria | Development of AKI within 7 days. | within 7 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Renal recovery | Defined as the absence of any stage of AKI by either serum creatinine or urine output criteria at hospital discharge. | Within 1 month |
The Effect of Directional Specific Thoracic Spine Mobilization on Cervical Spine Pain

Study Overview
=================
Brief Summary
-----------------
Hypothesis: There is no difference in directional specific manipulation of the thoracic spine for patients with neck pain. Patients seeking physical therapy for neck pain routinely have their thoracic spine manipulated. This study seeks to determine if directional limitations in the spine can be specifically determined and treated to decrease neck pain.

Detailed Description
-----------------
Manipulation of the thoracic spine is the most commonly used manual therapy intervention by manual therapists. It is not known whether we can accurately assess and treat directional limitations in the thoracic spine to improve neck pain. One way is to assess where the limitation is and treat it. Another method is to distract the joint. We want to know if matching the limitation to the manipulation method will give patients with neck pain better results. The patient lays on their back. The therapist places a hand on the inferior vertebrae of the motion segment. The patient relaxes and the therapist pushes in an anterior to posterior direction either moving the vertebrae into flexion or entension.

Official Title
-----------------
The Effect of Directional Specific Thoracic Spine Mobilization on Cervial Spine Pain.

Conditions
-----------------
Neck Pain

Intervention / Treatment
-----------------
* Other: thoracic spine manipulation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with Neck Pain; ages 18 - 60 Exclusion Criteria: red flags: leg weakness, night pain, history of cancer, upper motor neuron signs, infection, tumors, osteoporosis, fracture (Boissonnault, 2011) (Cleland, 2004) history of whiplash within 6 weeks, cervical stenosis, CNS involvement, signs consistent with nerve root compression, previous surgery, pending legal action

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Matched Group<br>Receives thoracic spine manipulation in the direction of motion limitation. | Other: thoracic spine manipulation<br>* a manual technique applied to the mid back to promote motion<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Neck Disability Index | Objective, valid, reliable measure of function in patients with neck pain. Completed as a survey. | 2 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Neck Pain | Selection of 0 to 10 level of pain. | 2 weeks |